LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

Iovance Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

2.2 -0.9

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.2

Max

2.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.5M

-112M

Verkäufe

11M

60M

Gewinnspanne

-186.246

Angestellte

838

EBITDA

8.3M

-102M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+363.91% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

6. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-124M

821M

Vorheriger Eröffnungskurs

3.1

Vorheriger Schlusskurs

2.2

Nachrichtenstimmung

By Acuity

100%

0%

353 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Iovance Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Sept. 2025, 23:01 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17. Sept. 2025, 22:48 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17. Sept. 2025, 21:59 UTC

Ergebnisse

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17. Sept. 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17. Sept. 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17. Sept. 2025, 22:20 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17. Sept. 2025, 22:19 UTC

Akquisitionen, Fusionen, Übernahmen

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17. Sept. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17. Sept. 2025, 21:00 UTC

Ergebnisse

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17. Sept. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17. Sept. 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17. Sept. 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17. Sept. 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17. Sept. 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17. Sept. 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17. Sept. 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17. Sept. 2025, 17:15 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17. Sept. 2025, 17:06 UTC

Akquisitionen, Fusionen, Übernahmen

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17. Sept. 2025, 16:51 UTC

Ergebnisse

Correct: Exor 1H Net Loss -EUR624M

17. Sept. 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. Sept. 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17. Sept. 2025, 16:25 UTC

Ergebnisse

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17. Sept. 2025, 16:23 UTC

Ergebnisse

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer-Vergleich

Kursveränderung

Iovance Biotherapeutics Inc Prognose

Kursziel

By TipRanks

363.91% Vorteil

12-Monats-Prognose

Durchschnitt 10.67 USD  363.91%

Hoch 20 USD

Tief 1 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Iovance Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

5

Buy

2

Halten

1

Sell

Technischer Score

By Trading Central

3.0208 / 3.5Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
help-icon Live chat